Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein
Format: Artigo
Idioma:Inglês
Publicat: NIHR Journals Library 2010-01-01
Col·lecció:Health Technology Assessment
Matèries:
bevacizumab
sorafenib-tosylate
sunitinib
temsirolimus
renal-cell-carcinoma
systematic-review
economic-evaluation
Accés en línia:https://doi.org/10.3310/hta14020
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars